A recent article published in the Journal of Public Library of Science, has provided findings of a new study that “nicotine chewing gum, lozenges and inhalers designed to help people to give up smoking may have the potential to cause cancer …”
The study, funded by the Medical Research Council at the University of London, specifically found that “using oral nicotine replacement therapies for long periods could contribute to a raised risk of the disease.” Additionally, the study concluded that “the effects of a genetic mutation that is common in mouth cancer can be worsened by nicotine in the levels that are typically found in smoking cessation products.”
A widely used nicotine chewing gum, Nicorette®, is manufactured by the pharmaceutical manufacturer GlaxoSmithKline. Such products typically advise users to “cut down after three months of use and to stop completely after six months.” There is no warning on such products that long-term use can cause or increase the risk of cancer.
If you or someone you know has developed cancer from the use of such nicotine replacement therapies, please immediately contact our law firm for a free-consultation.